Condition: Triple-Negative Breast Cancer (TNBC) · Sponsor: Qilu Pharmaceutical Co., Ltd.
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
This description comes directly from the study's public registry record.
Xiaoyan Xing, PhD · +86 21 5855 6098 · xingxiaoyan@escugen.com
Fei Ma, PhD
Always discuss trial participation with your own doctor first.
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06732323